Top Markets
Coin of the day
Thalia Therapeutics Plc Thalia Therapeutics Plc

Thalia Therapeutics Plc

THAT
Classifica tra le azioni #40823
Thalia Therapeutics Plc, a specialized pharmaceutical company established in... Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Prezzo delle azioni
$0.00918474
Capitalizzazione di mercato
$76.44K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
38.04%
Paese
GB
Scambia Thalia Therapeutics Plc (THAT)

Categoria

EPS per Thalia Therapeutics Plc (THAT)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Thalia Therapeutics Plc, l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per Thalia Therapeutics Plc da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE